Cutaneous Lupus Erythematosus – Pipeline Insight, 2020
![](/report_cover/8047/cutaneous-lupus-erythematosus-pipeline-insights-2015_en.gif)
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Cutaneous Lupus Erythematosus – Pipeline Insight, 2020,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cutaneous Lupus Erythematosus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Cutaneous Lupus Erythematosus: Overview
Lupus erythematosus (LE) is a connective tissue disease and autoimmune disorder that can affect one or several organs. Circulating autoantibodies and immune complexes are due to loss of normal immune tolerance and are pathogenic. The clinical features of LE are highly variable. LE nearly always affects the skin to some degree. Cutaneous LE comprises several chronic and relapsing LE-specific and LE-nonspecific inflammatory conditions. There can be some overlap:
A skin biopsy may be diagnostic, showing a lichenoid tissue reaction and features specific to the kind of cutaneous LE. Direct immunofluorescence tests may show positive antibody deposition along the basement membrane (lupus band test).
Treatment
Treatment may vary depending upon type of Cutaneous Lupus Erythematosus: The aim of treatment for cutaneous LE is to prevent flares, improve appearance and to prevent scarring.
Local therapy
Treatment for cutaneous and systemic LE may include:
This segment of the Cutaneous Lupus Erythematosus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cutaneous Lupus Erythematosus Emerging Drugs
Further product details are provided in the report
Cutaneous Lupus Erythematosus: Therapeutic Assessment
This segment of the report provides insights about the different Cutaneous Lupus Erythematosus drugs segregated based on following parameters that define the scope of the report, such as:
Cutaneous Lupus Erythematosus: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cutaneous Lupus Erythematosus therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cutaneous Lupus Erythematosus drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Cutaneous Lupus Erythematosus – Pipeline Insight, 2020,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cutaneous Lupus Erythematosus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Cutaneous Lupus Erythematosus: Overview
Lupus erythematosus (LE) is a connective tissue disease and autoimmune disorder that can affect one or several organs. Circulating autoantibodies and immune complexes are due to loss of normal immune tolerance and are pathogenic. The clinical features of LE are highly variable. LE nearly always affects the skin to some degree. Cutaneous LE comprises several chronic and relapsing LE-specific and LE-nonspecific inflammatory conditions. There can be some overlap:
- LE-specific cutaneous LE has been classified as acute, subacute, intermittent and chronic. Lesions may be localised or generalised. In LE-specific cutaneous LE, lesions are often induced by exposure to sunlight.
- LE-nonspecific cutaneous LE may relate to systemic LE or another autoimmune disease.
A skin biopsy may be diagnostic, showing a lichenoid tissue reaction and features specific to the kind of cutaneous LE. Direct immunofluorescence tests may show positive antibody deposition along the basement membrane (lupus band test).
Treatment
Treatment may vary depending upon type of Cutaneous Lupus Erythematosus: The aim of treatment for cutaneous LE is to prevent flares, improve appearance and to prevent scarring.
Local therapy
- Potent or ultrapotent topical steroids are applied to chronic discoid LE plaques.
- Calcineurin inhibitors, pimecrolimus cream or tacrolimus ointment can be used instead of topical steroids.
- Intralesional corticosteroid can be injected into small lesions resistant to topical therapy.
- Topical retinoids, calcipotriol and imiquimod have also been reported to be helpful in a few patients.
- Cosmetic camouflage may be used to disguise unsightly plaques.
Treatment for cutaneous and systemic LE may include:
- Antimalarials especially hydroxychloroquine
- Immune modulators such as methotrexate, mycophenolate, dapsone, ciclosporin
- Retinoids, ie acitretin, isotretinoin
- Systemic corticosteroids
- If sun protection is strict, vitamin D supplementation.
This segment of the Cutaneous Lupus Erythematosus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cutaneous Lupus Erythematosus Emerging Drugs
- Filgotinib: Galapagos/Gilead Sciences
- VIB7734: Viela Bio.
- HT-005 Z-Pods: Hoth Therapeutics/Zylo Therapeutics
Further product details are provided in the report
Cutaneous Lupus Erythematosus: Therapeutic Assessment
This segment of the report provides insights about the different Cutaneous Lupus Erythematosus drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Cutaneous Lupus Erythematosus
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Gene therapies
- Small molecule
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
- Product Type
Cutaneous Lupus Erythematosus: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cutaneous Lupus Erythematosus therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cutaneous Lupus Erythematosus drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cutaneous Lupus Erythematosus R&D. The therapies under development are focused on novel approaches to treat/improve Cutaneous Lupus Erythematosus.
- In May 2020, Viela Bio announced positive interim phase Ib data from a study with VIB7734, its novel anti-ILT7 therapy, in patients with cutaneous lupus erythematosus (CLE).
- In July 2019, Gilead Sciences and Galapagos stated that they have entered into a 10-year global research and development collaboration. Through this agreement, Gilead will gain access to an innovative portfolio of compounds, including six molecules currently in clinical trials, more than 20 preclinical programs and a proven drug discovery platform.
- In May 2020, Hoth Therapeutics announced it has completed a strategic investment in Zylц Therapeutics.
- Cutaneous Lupus Erythematosus Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cutaneous Lupus Erythematosus drugs?
- How many Cutaneous Lupus Erythematosus drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cutaneous Lupus Erythematosus?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cutaneous Lupus Erythematosus therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cutaneous Lupus Erythematosus and their status?
- What are the key designations that have been granted to the emerging drugs?
- Hoth Therapeutics
- Zylo Therapeutics
- Galapagos
- Gilead Sciences
- Viela Bio
- Biogen Idec
- Rigel Pharmaceuticals
- Amgen/AstraZeneca
- GSK2646264
- Filgotinib
- Daxdilimab
- BIIB 059
- R 333
- AEA-loaded Z-pods
- Prezalumab
Introduction
Executive Summary
Cutaneous Lupus Erythematosus: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cutaneous Lupus Erythematosus – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Cutaneous Lupus Erythematosus companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cutaneous Lupus Erythematosus Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Filgotinib: Galapagos/Gilead Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
VIB7734: Viela Bio.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
HT-005 Z-Pods: Hoth Therapeutics/Zylo Therapeutics
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Cutaneous Lupus Erythematosus Key Companies
Cutaneous Lupus Erythematosus Key Products
Cutaneous Lupus Erythematosus- Unmet Needs
Cutaneous Lupus Erythematosus- Market Drivers and Barriers
Cutaneous Lupus Erythematosus- Future Perspectives and Conclusion
Cutaneous Lupus Erythematosus Analyst Views
Cutaneous Lupus Erythematosus Key Companies
Appendix
Executive Summary
Cutaneous Lupus Erythematosus: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cutaneous Lupus Erythematosus – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Cutaneous Lupus Erythematosus companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cutaneous Lupus Erythematosus Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Filgotinib: Galapagos/Gilead Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
VIB7734: Viela Bio.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
HT-005 Z-Pods: Hoth Therapeutics/Zylo Therapeutics
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Cutaneous Lupus Erythematosus Key Companies
Cutaneous Lupus Erythematosus Key Products
Cutaneous Lupus Erythematosus- Unmet Needs
Cutaneous Lupus Erythematosus- Market Drivers and Barriers
Cutaneous Lupus Erythematosus- Future Perspectives and Conclusion
Cutaneous Lupus Erythematosus Analyst Views
Cutaneous Lupus Erythematosus Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Cutaneous Lupus Erythematosus
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Cutaneous Lupus Erythematosus
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Cutaneous Lupus Erythematosus
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Cutaneous Lupus Erythematosus
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products